Concepedia

Author

Michael Aboud

ViiV Healthcare (United Kingdom)ORCID

Also Known As

Allan R Tenorio, Cindy Vavro, M Aboud, M. Aboud, Manar Mahmoud Mohamed Aboud, Michael Aboud, Michael R Keegan

63

Publications

2.7K

Citations

19

H-Index

21

Concepts

All Affiliations

ViiV Healthcare (United Kingdom)GlaxoSmithKline (United Kingdom)TriangleNational Taiwan University HospitalViiV Healthcare (Spain)
MA

About

Michael Aboud is an author at ViiV Healthcare (United Kingdom) specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

1.1K

2

Public Health

2

2

385

3

Epidemiology

2

2

54

4

Immunology

2

2

230

5

Pathology

1

1

40

Michael Aboud

×

22

Publications

2.3K

Citations

16

H-Index

YearCitations

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas,

The Lancet

2018

371

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson,

The Lancet

2018

338

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop,

Clinical Infectious Diseases

2020

257

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2019

201

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard,

The Lancet Infectious Diseases

2019

190

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Amy Cutrell, Jonathan Schapiro, Carlo Federico Perno,

AIDS

2021

189

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana,

Clinical Infectious Diseases

2022

123

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Michael Aboud, Chloe Orkin, Daniel Podzamczer,

The Lancet HIV

2019

110

Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Benoît Trottier, Jordan E. Lake, Ken Logue,

Antiviral Therapy

2016

106

Psychiatric Symptoms in Patients Receiving Dolutegravir

Anna Fettiplace, Chris Stainsby, Alan Winston,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2016

99

Page 1